GlassScriptPhysician profile
Norman C Nelson
NPI 1518995810
$1,061.78
in general payments reported to CMS, 2019-2025
15 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.06 · 2020: $105 · 2021: $56.22 · 2022: $169 · 2023: $264 · 2024: $120 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $238.42 | 2021-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $186.74 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $141.13 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $104.83 | 2020 | |
| Abbvie INC. | $87.02 | 2022-2023 | |
| Biogen, INC. | $70.59 | 2023 | |
| Alimera Sciences, INC. | $40.28 | 2022-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $38.31 | 2024-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $33.89 | 2019 | |
| Harrow Eye, LLC | $24.48 | 2025 | Iheezo |
| Coherus Oncology, INC. | $24.23 | 2023 | |
| Bausch & Lomb Americas INC. | $23.73 | 2025 | Xipere, Visudyne |
| Amgen INC. | $19.67 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $16.51 | 2022 | |
| Allergan, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.